drugset / Trial / NCT05522816

KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis

NCT05522816

Phase 1 Completed 28 enrolled PharmaEssentia
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 in the treatment of patients with plaque-type psoriasis.

Timeline

Start
2015-10-27
Primary completion
2021-03-10
Completion
2021-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirbanibulin Small molecule 0.01 % Topical
Subject Tirbanibulin Small molecule 0.1 % Topical
Subject Tirbanibulin Small molecule 1 % Topical

Indications